Quality Systems – Page 246

Sedimentation Oos in ear drop manufacturing: sanitation, water, and EM checks

Investigating the Causes and Solutions of Sedimentation OOS in Ear Drop Manufacturing In the highly regulated environment of pharmaceutical manufacturing, deviations, out-of-specification (OOS) results, and complaints must be investigated thoroughly…

Oos Release Profile for long-acting injectables: how to document for FDA/EMA/MHRA review

Documenting OOS Release Profiles for Long-Acting Injectables: Best Practices for Regulatory Review In the pharmaceutical manufacturing landscape, deviations from expected operational standards can profoundly impact product viability, particularly for long-acting…

Stability Failure after formulation change: control strategy build-out for inspections

Addressing Stability Failures Following Formulation Changes: An Investigation Framework In pharmaceutical manufacturing, formulation changes can lead to unexpected stability failures, prompting deviations or out-of-specification (OOS) results. Such incidents are critical…

API heavy metals / elemental impurities OOS after re-crystallization parameter adjustment: supplier qualification gaps and incoming testing upgrades to close the loop

Investigating OOS Results of API Heavy Metals After Re-crystallization Parameter Adjustments In pharmaceutical manufacturing, the identification of Out-of-Specification (OOS) results regarding heavy metals or elemental impurities post-re-crystallization presents significant compliance…

Phase Separation during method transfer: investigation steps with CAPA evidence

Investigating Phase Separation during Method Transfer: Effective Investigation Steps and CAPA Solutions Phase separation occurring during method transfer is a vital issue that can compromise product integrity in pharmaceutical manufacturing,…

Scale-Up Failure for long-acting injectables: risk assessment and validation impact analysis

Addressing Scale-Up Failure in Long-Acting Injectables: A Comprehensive Investigation Approach Scale-up failures in the manufacturing of long-acting injectables can lead to significant deviations from expected performance, impacting product quality and…

Ivivc Mismatch during PAI readiness: regulatory-ready investigation and CAPA plan

Understanding Ivivc Mismatch during PAI Readiness: A Comprehensive Investigation Approach In the intricate landscape of pharmaceutical manufacturing, ensuring that in vitro-in vivo correlation (IVIVC) aligns during Pharmacokinetic Assessment for submission…

Ivivc Mismatch for modified release platforms: how to document for FDA/EMA/MHRA review

Documenting Ivivc Mismatch for Modified Release Platforms for Regulatory Review The pharmaceutical landscape continually evolves, with modified release platforms presenting unique challenges for quality control (QC) and quality assurance (QA)…

API batch-to-batch variability trend (OOT) during process validation campaign: root cause analysis (process vs lab) with CAPA effectiveness checks

Root Cause Analysis of API Batch-to-Batch Variability Trends During Process Validation Campaigns In pharmaceutical manufacturing, ensuring consistent product quality is paramount. Variability in Active Pharmaceutical Ingredient (API) batches can lead…

Tag: Quality Systems